99 results
Page 3 of 5
8-K
EX-99.1
iv5366v3zu5u9
6 May 21
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
EX-99.1
ktpxjheu2p k3
20 Apr 21
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
4:44pm
8-K
EX-99.1
ylmggky8
25 Feb 21
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
8:00am
8-K
EX-99.1
0ybjs wvbhylfq
10 Nov 20
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.2
wcg7vwrzesj20ihs jp
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
x0f79sk
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
0kiy wyfrih2ouik
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.2
u63yxzk5754pcgtcnw5
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
9n4q t4016b4h
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.1
qugkkbmg
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.2
z02dovy
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
424B5
lfh0ssllpk3qvt3d8
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
4micu5lse6k1148zv
19 May 20
Prospectus supplement for primary offering
5:08pm
FWP
9zykgvq
19 May 20
Free writing prospectus
6:06am
FWP
oy3sx
18 May 20
Free writing prospectus
5:02pm